上海莱士：公司及合并范围内子公司拟申请开展外汇衍生品业务

Group 1 - The company has acquired Nanyue Biological for 4 billion, despite its valuation being only 880 million, raising concerns about potential interests transfer and damage to minority shareholders' interests [1][2] - The acquisition is part of a strategic plan to enhance the company's position in the blood products industry, focusing on regional collaboration and increasing plasma collection capacity [1][2] - The funding for the acquisition will come from the company's own and raised funds, ensuring no significant adverse impact on financial status or operations [2] Group 2 - The company plans to engage in foreign exchange derivatives trading to mitigate risks associated with currency fluctuations, which requires approval from the shareholders' meeting [2] - The company has terminated the planned major asset restructuring with Haier Biological due to the complexity of the transaction and lack of consensus among involved parties [2] - The management asserts compliance with laws and regulations, emphasizing that there is no harm to the interests of the company or its shareholders, particularly minority shareholders [2]